Humira is a brand name for the drug adalimumab [1]. It is used to treat several autoimmune conditions [1].
What is Adalimumab Used For?
Adalimumab, marketed as Humira, is prescribed for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [1]. It is also used to treat juvenile idiopathic arthritis and uveitis in certain age groups [1].
How Does Humira Work?
Humira is a biologic medication that works by blocking a protein called tumor necrosis factor-alpha (TNF-alpha) [1]. TNF-alpha is a substance produced by the body that causes inflammation in the conditions treated by Humira [1]. By inhibiting TNF-alpha, adalimumab reduces inflammation and its associated symptoms [1].
When Does Humira's Patent Expiration Date?
The primary patents for Humira have expired or are nearing expiration in major markets. For instance, in the United States, key patents began to expire around 2016, with further expansions and settlements impacting later dates [2]. In Europe, patent expiries have also occurred, leading to the availability of biosimilars [3]. DrugPatentWatch.com tracks these patent expirations and provides detailed information on patent landscapes for various drugs [2].
Can Biosimilars Be Made for Humira?
Yes, biosimilar versions of adalimumab have been developed and approved in various regions. These biosimilars are highly similar to Humira and are intended to offer comparable safety and efficacy. The introduction of biosimilars follows the expiry of primary patents [3].
Who Makes Humira and Its Biosimilars?
Humira is manufactured by AbbVie [1]. Several companies have developed and launched biosimilar versions of adalimumab, including Amgen (Amjevita), Boehringer Ingelheim (Cyltezo), Samsung Bioepis (Hadlima), and Sandoz (Hyrimoz), among others, depending on the specific market and patent status [2][3].
What Are the Risks Associated with Humira?
Like all medications, Humira carries potential risks. These include an increased risk of serious infections, as it suppresses the immune system [1]. Other potential side effects can involve reactions at the injection site, headaches, and nausea [1]. Patients considering Humira should discuss all potential risks and benefits with their healthcare provider [1].
---
Sources:
1. https://www.drugpatentwatch.com/drug/adalimumab/humira
2. https://www.drugpatentwatch.com/drug/adalimumab
3. https://www.drugpatentwatch.com/us/adalimumab-biosimilar-launch-date